Clinical Trial Update: Adjunctive Effects of Psilocybin and a Formulation of Buprenorphine [Phase 1]

View source ↗

Summary

Phase 1 clinical trial investigating adjunctive effects of psilocybin with a buprenorphine formulation for opioid use disorder; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Opioid Use Disorder

Drugs mentioned

• Psilocybin (psilocybin)
• buprenorphine (buprenorphine)

Snippet

Sponsor: University of Wisconsin, Madison | Conditions: Opioid Use Disorder | Phase 1 | Status: RECRUITING